| Document |
Document Title |
|
WO/2023/069700A1 |
Described herein, in part, are compounds that mediate the degradation of cyclin-dependent kinase 2 (CDK2), and are therefore useful in the treatment of various disorders, such as cancer.
|
|
WO/2023/069644A1 |
The present invention relates to the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinazoline structure or a quinoline structure according to Formula (I), wherein L, R1, R2...
|
|
WO/2023/069544A1 |
The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.
|
|
WO/2023/069458A1 |
Crystalline forms of (S)-1-(1-acryloylpiperidin-3-yl)-2-fluoro-5,6,7,8,9,10-hexah
ydrocyclo hepta[b]indole-4-carboxamide are provided. Pharmaceutical compositions containing (S)-1-(1-acryloylpiperidin-3-yl)-2-fluoro-5,6,7,8,9,10-hexah
yd...
|
|
WO/2023/069708A1 |
Described herein, in part, are compounds that bind to and modulate the surface of cereblon and mediate the degradation of GSPT1, and are therefore useful in the treatment of various disorders, such as cancer.
|
|
WO/2023/069547A1 |
The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.
|
|
WO/2023/068755A1 |
The present invention relates to a novel compound having an inhibitory effect on fibrosis. The present inventors found that the compound had the effect of inhibiting actin polymerization, and reduced not only the levels of various fibros...
|
|
WO/2023/069720A1 |
Described herein, in part, are compounds that mediate the degradation of cyclin-dependent kinase 2 (CDK2), and are therefore useful in the treatment of various disorders, such as cancer.
|
|
WO/2023/066363A1 |
A compound represented by formula (I), a stereoisomer, deuterated compound, solvate, pharmaceutically acceptable salt or co-crystal thereof, or a pharmaceutical composition containing them, and use of the compound as a PARP-1 inhibitor i...
|
|
WO/2023/066377A1 |
A compound represented by formula (I), a solvate thereof, a pharmaceutically acceptable salt thereof, or a solvate of the pharmaceutically acceptable salt thereof, a preparation method therefor and an application thereof. The nitrogen-co...
|
|
WO/2023/066834A1 |
The present invention relates to compounds of formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, intermediate compounds useful in such preparations, pharmaceutical compositions contai...
|
|
WO/2023/067170A1 |
Bis(aminostyrylpyridinium) compounds of formula (I) and pharmaceutical acceptable salts thereof are provided for use as a medicament. Additionally, multiple novel bis(aminostyrylpyridinium) compounds of formula (I) are provided. The pres...
|
|
WO/2023/067354A1 |
The invention relates to heterocyclic derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation.
|
|
WO/2023/062647A1 |
The present invention discloses formulation comprising more than 50 % of Isomalt as a diluent. More specifically the present invention provides a stable capsule formulation of Pomalidomide with Isomalt and its methods of preparation.
|
|
WO/2023/063751A1 |
The present disclosure provides novel compounds exhibiting inhibitory activity against ALK overexpression, ALK mutation, EGFR overexpression, EGFR mutation, etc., and a medical use thereof. The present disclosure provides a pharmaceutica...
|
|
WO/2023/061406A1 |
A PARP inhibitor containing a fused tri-cyclic structure, and a preparation method therefor and the medical use thereof. Specifically, the present invention relates to a new compound as represented by general formula (1) and/or a pharmac...
|
|
WO/2023/060362A1 |
There is provided a compound of formula (I), and its use for inhibiting RAS (wild type or mutant), for example HRAS, NRAS, and/or KRAS, and for the prevention or treatment of a disease or disorder associated with abnormal RAS activity, f...
|
|
WO/2023/061617A1 |
The present invention relates to compounds of formula (I), wherein R1 to R3, A, Q1, Q2, W and X are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using th...
|
|
WO/2023/064223A1 |
Described hereina re trisubstituted pyridine compounds compounds useful in the modulation of IL-12, IL-23 and/or IFNα by acting on TYK2 to cause signal transduction inhibition, as well as to pharmaceutical compositions containing the sa...
|
|
WO/2023/061440A1 |
Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are bifunctional compounds having a DNA damage-binding protein 1 (DDB1) binding moiety, a linker, a...
|
|
WO/2023/061368A1 |
The present invention provides a hydroximic acid derivative and a use thereof, which relate to the field of biomedicine. The hydroximic acid derivative is a compound represented by formula I, or a salt thereof, or a stereoisomer thereof,...
|
|
WO/2023/063697A1 |
The present invention relates to a series of novel pyrazolylmethylurea derivatives, and the use thereof for the inhibition of capsid assembly and the prevention or treatment of viral diseases through the inhibition.
|
|
WO/2023/061492A1 |
Provided are a compound of formula (I), a pharmaceutically acceptable salt thereof, a stereoisomer thereof, or an isotope marker thereof; a pharmaceutical composition containing the compound of formula (I); and the use of the compound of...
|
|
WO/2023/064880A1 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
|
WO/2023/064920A1 |
The present disclosure provides novel crystalline forms of a compound that acts as a CDK9 modulator, processes for preparing the novel crystalline forms of a compound that acts as a CDK9 modulator, and uses thereof.
|
|
WO/2023/063698A1 |
The present invention relates to a series of novel triazolomethylurea derivatives, and the use thereof for the inhibition of capsid assembly and the prevention or treatment of viral diseases through the inhibition.
|
|
WO/2023/057457A1 |
The present invention relates to ligands of Fibroblast Activation Protein (FAP) for the active delivery of radioactive payloads at the site of disease. In particular, the present invention relates to the development of FAP ligands for th...
|
|
WO/2023/059605A1 |
The invention provides heterobifunctional compounds, pharmaceutical compositions, and their use in treating disease, such as cancer.
|
|
WO/2023/059609A1 |
The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from GSPT1, Cyclin K, RBM23, RBM39, IKZF1, IKZF3, PLK1, CDK4 or CKlalpha which is linked to a moiety that binds to a target protei...
|
|
WO/2023/059581A1 |
The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from mTor, PLK1, CDK1, CDK2, CDK9, BRD4, AURKA, AURKB, MEK, Src, c-KIT, KIF11, HSP90, tubulin, proteasome, topoisomerase or HD AC ...
|
|
WO/2023/060057A1 |
Described here are compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and their use and preparation.
|
|
WO/2023/060202A1 |
Provided herein are pyrazole compounds. In particular, provided herein are compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds provided herein are us...
|
|
WO/2023/058645A1 |
Provided is a technique for improving the productivity in a method for producing a compound I or a pharmaceutically acceptable salt thereof. This method for producing the compound I has: a step for preparing a compound 16 solution by dep...
|
|
WO/2023/057429A1 |
There are disclosed certain 2,5-diazabicyclo[4.2.0]octanes of formula (I) and octahydrofuro[3,4-b]pyrazines, and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compound...
|
|
WO/2023/057548A1 |
The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the prevention or treatment of e.g. inflammatory/autoimmune diseases/disorders and cancer.
|
|
WO/2023/059899A1 |
The present application discloses novel compounds, pharmaceutical compositions containing these compounds and methods of inducing degradation of a protein, comprising contacting the protein with an effective amount of a compound of the d...
|
|
WO/2023/051749A1 |
The present invention relates to an AAK1 inhibitor and the use thereof. Specifically, the present invention relates to a compound as represented by formula I, a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt o...
|
|
WO/2023/051716A1 |
Provided are a compound represented by formula (I), a stereoisomer, pharmaceutically acceptable salt, solvate and eutectic or deuterated material thereof, or a pharmaceutical composition comprising same, and a use thereof as a PARP-1 inh...
|
|
WO/2023/055952A1 |
Compounds that degrade one or more neurotrophic tyrosine receptor kinase (NTRK) proteins for the treatment of NTRK mediated disorders are provided.
|
|
WO/2023/051686A1 |
Embodiments of the present application provide a photosensitive molecule, a photoacid generator containing the photosensitive molecule, and a photosensitive resin composition. The molecular structure of the photosensitive molecule compri...
|
|
WO/2023/056039A1 |
Described herein are azetidine and pyrrolidine PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
|
|
WO/2023/054759A1 |
The present invention relates to a 2-aminoquinazoline derivative or a pharmaceutically acceptable salt thereof and, more specifically, to a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof, and an ...
|
|
WO/2023/054715A1 |
The present invention provides a method for producing a compound through a cross-coupling reaction, wherein: the method for producing a compound includes reacting a compound 1 having a leaving group X1 on a carbon atom of an aromatic rin...
|
|
WO/2023/053039A1 |
Provided herein are novel compounds having an inhibitory effect on the activation of a STING pathway. The provided compounds are 1,2-diaminobenzimidazole derivatives represented by a compound formula (I) or a pharmaceutically acceptable ...
|
|
WO/2023/053009A1 |
The present invention relates to pyridines and their use for increasing GBA activity and/or levels as well as treatment of GBA-related diseases, such as Parkinson's disease.
|
|
WO/2023/051812A1 |
Provided are a compound represented by formula (I), a stereoisomer, pharmaceutically acceptable salt, solvate, and eutectic or deuterated compound thereof, or a pharmaceutical composition comprising same, and a use thereof as a PARP-1 in...
|
|
WO/2023/051687A1 |
Provided are a quinazoline compound, a composition, and an application thereof, in particular, a compound represented by formula (I), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a composition thereof, and an appli...
|
|
WO/2023/052354A1 |
The present disclosure relates to the compounds of formula (I) or their pharmaceutically acceptable salts, or their stereoisomers or mixtures of stereoisomers, either of the compound of formula (I) or of any of its pharmaceutically accep...
|
|
WO/2023/054344A1 |
The problem to be solved by the present invention is to provide: a compound which is useful as a hole transport material for photoelectric conversion elements that are capable of efficiently taking out electric current; and a photoelectr...
|
|
WO/2023/050104A1 |
The present invention relates to the technical field of medicines. Specifically disclosed are an indoline derivative, a preparation method therefor, a pharmaceutical composition, and use. In particular, the present invention relates to a...
|
